Cargando…
The renin–angiotensin system blockers and survival in digestive system malignancies: A systematic review and meta-analysis
BACKGROUND: Accumulating pre-clinical and clinical studies suggested that the renin–angiotensin system blockers (RASBs) possess anti-carcinogenic properties, and their use is associated with favorable outcomes in many types of cancers. METHODS: A systematic literature search of relevant databases th...
Autores principales: | Zhou, Qi, Chen, Di-Shi, Xin, Lin, Zhou, Li-Qiang, Zhang, Hou-Ting, Liu, Li, Yuan, Yi-Wu, Li, Shi-Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035076/ https://www.ncbi.nlm.nih.gov/pubmed/32049809 http://dx.doi.org/10.1097/MD.0000000000019075 |
Ejemplares similares
-
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020) -
Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021) -
Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023) -
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020) -
Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: A case report
por: Park, Dae Hwa, et al.
Publicado: (2017)